SCHEMBL23488170

SCHEMBL23488170

COc1c(Cl)c(OCc2ccccc2)c(Cl)c(C)c1C(=O)O[C@@H]1[C@H](O)[C@@H](O)[C@H](OC)O[C@@H]1CO

nearest known ligand 0.47

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
LGALS8 O00214 6/20 0.47
LGALS3 P17931 4/20 0.39
LGALS9 O00182 1/20 0.39
LGALS1 P09382 1/20 0.39
LGALS7; LGALS7B P47929 1/20 0.39
EPHX2 P34913 1/20 0.38
LGALS4 P56470 2/20 0.36
SELP P16109 2/20 0.36
SLC5A1 P13866 1/20 0.34
SLC5A2 P31639 1/20 0.34
KCNA3 P22001 1/20 0.34
SLC6A2 P23975 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23488522 1.00 LGALS8 (0.47) LGALS8LGALS3LGALS9LGALS1LGALS7; LGALS7B
SCHEMBL23488518 1.00 LGALS8 (0.47) LGALS8LGALS3LGALS9LGALS1LGALS7; LGALS7B
SCHEMBL23488158 0.93 LGALS8 (0.55) LGALS8LGALS3LGALS9LGALS1LGALS7; LGALS7B
SCHEMBL23488142 0.93 LGALS8 (0.47) LGALS8LGALS3LGALS9LGALS1LGALS7; LGALS7B
SCHEMBL23488694 0.93 LGALS8 (0.47) LGALS8LGALS3LGALS9LGALS1LGALS7; LGALS7B
SCHEMBL23488171 0.93 LGALS8 (0.47) LGALS8LGALS3LGALS9LGALS1LGALS7; LGALS7B
SCHEMBL23488712 0.93 LGALS8 (0.55) LGALS8LGALS3LGALS9LGALS1LGALS7; LGALS7B
SCHEMBL23488579 0.84 LGALS8 (0.40) LGALS8SLC5A1SLC5A2KCNA3SLC6A2
SCHEMBL23488516 0.84 LGALS8 (0.40) LGALS8SLC5A1SLC5A2KCNA3SLC6A2
SCHEMBL23488282 0.84 LGALS8 (0.40) LGALS8SLC5A1SLC5A2KCNA3SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210170033-A1 NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210170033-A1 NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 LGALS8 61/4885LGALS3 156/4885LGALS9 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.